📇 Rhumatologue · PARIS · (75) · Salarié

MME MARTINE BAGOT

Pourquoi vous devez consulter ce praticien

4 raisons identifiées

Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (1 thèse dirigée)
Référence presse grand public
Cité 2 fois dans les médias — pédagogie reconnue
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PARIS (75)SalariéRPPS 10001214021

📊 Reconnaissance scientifique : 51/100📝 428 articles publiés🇫🇷 Publications académiques françaises (8)🎓 1 thèse dirigée

✨ Génération du profil synthétique IA en cours…

Direction de thèses

🎓 1 thèse dirigée

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023

European journal of cancer (Oxford, England : 1990) · 2023

📚 125 citations🎯 RCR 21.94Top 1% NIH🔓 Open Access📄 PDF gratuit ↗

Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study

Lancet (London, England) · 2023

📚 47 citations🎯 RCR 6.50Top 5% NIH

International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies

Blood advances · 2023

📚 28 citations🎯 RCR 4.41Top 9% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Despite increasing availability of therapies, patients with Sezary syndrome (SS) commonly endure multi-line treatment journeys, mostly with partial responses of short duration. Measuring clinical benefit is challenging; time-to-next-treatment (TTNT) provides a robust, objective measurement of efficacy. This international observational study examines patterns of clinical care and therapeutic benefit as measured by TTNT. TTNT was calculated for monotherapies and combination therapies, with consideration to treatment line. 178 patients with SS (73% de novo, 27% secondary) were included, receiving 721 lines of systemic therapy, with median follow-up of 56.9 months. Across all lines, 58 different therapeutic regimens were prescribed (54 were systemic therapies) and classified into 17 treatment groups. The most common first-line treatments were extracorporeal photopheresis (ECP)–containing combination therapy (20%) and retinoid monotherapy (19%). Median TTNT for all first-line therapies was short (5.4 months). First-line, combination therapies had longer median TTNT than monotherapies, 10.0 vs 5.0 months (P = .004), respectively. Later delivery of combination therapies was associated with shorter clinical benefit, with median TTNT reduced to 6.2 and 2.2 months for mid-line (2nd-4th line) and late-line (≥5th line), respectively (P &lt; .001). First-line ECP-containing treatments were associated with longer median TTNT than non-ECP–containing treatments, 9.0 vs 4.9 months (P = .007). For both ECP-monotherapy and ECP–containing combination therapy, significant reductions in TTNT were seen in later lines. These data suggest therapeutic benefit from first-line delivery of combination therapy for SS and favor early inclusion of ECP in the treatment algorithm for those who can access it.

Cookies & analyse de trafic

MME MARTINE BAGOT

Pourquoi vous devez consulter ce praticien

Direction de thèses

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (2)

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal31

Recommandations7

Épidémiologie & registres3

Essai clinique3

Pédiatrie3

Revue générale2

csDMARDs1

Fièvres auto-inflammatoires1

Sclérodermie1

Vascularites des gros vaisseaux1

Vraie vie / RWE1

Datasets & protocoles partagés

Partager cette fiche